

# In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of *SDHx* Mutations in Paraganglioma

Charlotte Lussey-Lepoutre<sup>1,2</sup>, Alexandre Bellucci<sup>1,2</sup>, Aurélie Morin<sup>1,2</sup>, Alexandre Buffet<sup>1,2</sup>, Laurence Amar<sup>1,2,3</sup>, Maxime Janin<sup>2,4,5</sup>, Chris Ottolenghi<sup>2,4,5</sup>, Franck Zinzindohoué<sup>2,6</sup>, Gwennhael Autret<sup>1,2</sup>, Nelly Burnichon<sup>1,2,7</sup>, Estelle Robidel<sup>1,2</sup>, Benjamin Banting<sup>8</sup>, Sébastien Fontaine<sup>8</sup>, Charles-André Cuenod<sup>1,2,8</sup>, Paule Benit<sup>9,10</sup>, Pierre Rustin<sup>9,10</sup>, Philippe Halimi<sup>2,8</sup>, Laure Fournier<sup>1,2,8</sup>, Anne-Paule Gimenez-Roqueplo<sup>1,2,7</sup>, Judith Favier<sup>1,2</sup>, and Bertrand Tavitian<sup>1,2,8</sup>

## Abstract

**Purpose:** Germline mutations in genes encoding mitochondrial succinate dehydrogenase (SDH) are found in patients with paragangliomas, pheochromocytomas, gastrointestinal stromal tumors, and renal cancers. SDH inactivation leads to a massive accumulation of succinate, acting as an oncometabolite and which levels, assessed on surgically resected tissue are a highly specific biomarker of *SDHx*-mutated tumors. The aim of this study was to address the feasibility of detecting succinate *in vivo* by magnetic resonance spectroscopy.

**Experimental Design:** A pulsed proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS) sequence was developed, optimized, and applied to image nude mice grafted with *Sdhb*<sup>-/-</sup> or wild-type chromaffin cells. The method was then applied to patients with paraganglioma carrying (*n* = 5) or not (*n* = 4) an *SDHx* gene mutation. Following surgery, succinate was measured using gas

chromatography/mass spectrometry, and SDH protein expression was assessed by immunohistochemistry in resected tumors.

**Results:** A succinate peak was observed at 2.44 ppm by <sup>1</sup>H-MRS in all *Sdhb*<sup>-/-</sup>-derived tumors in mice and in all paragangliomas of patients carrying an *SDHx* gene mutation, but neither in wild-type mouse tumors nor in patients exempt of *SDHx* mutation. In one patient, <sup>1</sup>H-MRS results led to the identification of an unsuspected *SDHA* gene mutation. In another case, it helped define the pathogenicity of a variant of unknown significance in the *SDHB* gene.

**Conclusions:** Detection of succinate by <sup>1</sup>H-MRS is a highly specific and sensitive hallmark of *SDHx* mutations. This non-invasive approach is a simple and robust method allowing *in vivo* detection of the major biomarker of *SDHx*-mutated tumors. *Clin Cancer Res*; 22(5); 1120–9. ©2015 AACR.

<sup>1</sup>INSERM, UMR970, Paris Cardiovascular Research Center, Paris, France. <sup>2</sup>Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France. <sup>3</sup>Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service d'hypertension artérielle et médecine vasculaire, Paris, France. <sup>4</sup>Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Laboratoire de Biochimie Métabolique, Paris, France. <sup>5</sup>INSERM, U1124, Paris, France. <sup>6</sup>Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Chirurgie Digestive, Paris, France. <sup>7</sup>Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, Paris, France. <sup>8</sup>Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Radiologie, Paris, France. <sup>9</sup>INSERM, UMR1141, Hôpital Robert Debré, Paris, France. <sup>10</sup>Université Paris 7, Faculté de Médecine Denis Diderot, Paris, France.

**Note:** Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

J. Favier and B. Tavitian share senior authorship of this article.

C. Lussey-Lepoutre and A. Bellucci contributed equally to this article.

**Corresponding Author:** Judith Favier, INSERM, 56 rue Leblanc, Paris 75015, France. Phone: 33153988041; Fax: 33144253987952; E-mail: [judith.favier@inserm.fr](mailto:judith.favier@inserm.fr)

doi: 10.1158/1078-0432.CCR-15-1576

©2015 American Association for Cancer Research.

## Introduction

Pheochromocytoma and paraganglioma are rare neuroendocrine tumors that arise in chromaffin cells of the adrenal medulla and in sympathetic and parasympathetic ganglia, respectively. The prevalence of pheochromocytoma and paraganglioma (PPGL) in patients with hypertension consulting at general outpatient clinics is estimated at 0.2% to 0.6%, but this number may be underestimated (1). Nearly 40% of patients with PPGL carry a germline mutation in one of the 13 PPGL predisposing genes identified so far (2), and mutations of *SDHx* genes (*SDHA*, *SDHB*, *SDHC*, *SDHD*, *SDHAF2*) are causative of approximately half of the genetically determined cases. *SDHx* mutations predispose to the hereditary PPGL syndrome but may also be found in patients with gastrointestinal stromal tumors (GIST; ref. 3) or renal clear cell carcinomas (4).

*SDHA*, *B*, *C*, and *D* genes encode the four subunits of succinate dehydrogenase (SDH), a mitochondrial enzyme of the tricarboxylic acid (TCA) cycle that oxidizes succinate into fumarate. They were the first genes encoding a mitochondrial enzyme demonstrated to act as tumor suppressor genes (5), an important finding supporting the hypothesis of a direct link between mitochondrial dysfunction and cancer proposed by Warburg in 1924 (6). Since

### Translational Relevance

A large proportion of patients with paraganglioma/pheochromocytoma (PPGL) carry a germline mutation in an *SDHx* gene. Identification of *SDHx* mutations is important for the diagnostic work-up, the management, and the follow-up of patients with PPGL and their families, who are at risk of developing multiple paraganglioma. Moreover, *SDHB* gene mutations predispose to malignant, particularly aggressive forms of the disease. Therefore, a genetic counseling is now recommended for all patients suffering from PPGL. We here show that *in vivo* detection of succinate by proton magnetic resonance spectroscopy is a highly specific and sensitive hallmark of *SDHx* mutated tumors. This noninvasive approach will allow identifying and classifying *SDHx* mutations or variants of unknown significance. It may help for the characterization of inoperable tumors and suspicious lesions and serve as a surrogate biomarker in the assessment of tumor response to specific treatments.

then, mutations in genes encoding for the TCA enzymes fumarate hydratase (*FH*; ref. 7), isocitrate dehydrogenase (*IDH1* and 2; ref. 8), and more recently malate dehydrogenase (*MDH2*), were reported to predispose to PPGL, renal cancers, leiomyomas, or to be causative of sporadic gliomas (for review, see ref. 9).

Identification of *SDHx* mutations is important for the diagnostic work-up, the management, and the follow-up of index cases and their families. *SDHx* mutation carriers are at risk of developing multiple paraganglioma that can arise all along the embryonic migration way of neural crest cells, from the base of the skull to the pelvis (10). Moreover, the identification of *SDHB* gene mutations is of specific clinical importance as they predispose to malignant, particularly aggressive forms of the disease (11, 12), and a genetic counseling is now recommended for all patients suffering from PPGL (1). In familial PPGL patients carrying a germline heterozygous mutation on an *SDHx* gene, the somatic loss of the remaining allele induces a complete SDH loss-of-function, which results in the accumulation of succinate. Succinate acts as an oncometabolite and is suspected to mediate most, if not all, of the tumorigenic effects related to *SDHx* mutations (9, 13, 14). Development of specific tumor biomarkers allowing the rapid identification of these patients would be highly beneficial and particularly helpful for the characterization of inoperable tumors and suspicious lesions. Biomarkers could serve as surrogate markers in the assessment of tumor response to specific treatments. Until now, no *in vivo* method to assess the functional consequences of *SDHx* mutations was available, and all existing tests were performed on surgical resected specimens (15–22).

Succinate concentrations in the millimolar range—4 to 500 micromoles per gram depending on studies and procedures—have been reported in *SDHx*-mutated PPGL tumors, an increase of up to 100-fold compared with non-*SDHx*-mutated PPGL tumors (19, 21, 23). We hypothesized that these succinate levels could be detected noninvasively by *in vivo* proton magnetic resonance spectroscopy ( $^1\text{H}$ -MRS) in *SDHx*-mutated tumors, without the need for tissue sampling, similarly to 2-hydroxyglutarate in patients with *IDH1/2*-mutated gliomas (24–26). Here, we report a new method for Succinate Estimation by Spectroscopy

(SUCCES) in patients with PPGL related or not to an *SDHx* mutation.

### Materials and Methods

#### Optimization of SUCCES for succinate detection with $^1\text{H}$ -MRS

We first tested the SUCCES sequence at 4.7 T on a 3-cm-diameter spherical phantom tube containing 100 mmol/L sodium succinate dibasic hexahydrate, 100 mmol/L L-lactate, and animal fat. Spectra and signal intensities acquired with different echo times (TE) ranging from 12.8 to 792 ms are shown in Supplementary Fig. S1A and S1B. The gradual decrease of the lipid signal with increasing TE eventually unmasked the succinate peak at TE > 70 ms and the lactate peak at TE > 100 ms. As previously described (27), increasing TE reduced the succinate signal exponentially and the lactate peak sinusoidally due to scalar coupling effect (Supplementary Fig. S1B). To study both the succinate and lactate signals, we chose a TE of 272 ms that reduced fat contamination and yielded positive lactate and succinate peaks. We then performed  $^1\text{H}$ -MRS spectra with decreasing (10–1 mmol/L) concentrations of succinate and lactate [repetition time (TR), 3000 ms; echo time (TE), 272 ms; average, 128; volume of interest (VOI) size,  $5 \times 5 \times 5 \text{ mm}^3$ ]. Water suppression was performed using VAPOR pulses (sinc RF pulses, 646 ms total duration, 700 Hz bandwidth), followed by crusher gradients (3 ms duration, 58 mT/m strength). Three-sinc-shaped RF pulses with 4 kHz bandwidth to obtain a spectral width of 20 ppm achieved VOI selection. Spectral resolution was 0.98 Hz/point. After zero filling and phase correction, data filtration was performed with a Gaussian function at the top of the Free Induction Decay, with a length band of 2 Hz and visualization was obtained with a Fourier transform. The area under the succinate peak measured from the spectra was linearly correlated with the succinate concentration (Supplementary Fig. S1C and S1D).

A similar procedure was performed in the 3T clinical scanner using 3-cm-diameter phantom tubes and a larger VOI size ( $10 \times 10 \times 10 \text{ mm}^3$ ), except that the TR was 2,500 ms and the TE was lowered to 144 ms to compensate the lower detection threshold and the decrease of the signal-to-noise ratio (Supplementary Fig. S1E). On the basis of these procedures, the threshold for succinate detection was found to be approximately 1 mmol/L in both magnets.

#### Generation of the allografted mouse model

No animal model of SDH-related PPGL being available, we generated an allografted mouse model by subcutaneous injection of  $2.5 \times 10^6$  immortalized mouse chromaffin cells (imCC; ref. 13) carrying a homozygous knockout of the *Sdhb* gene (*Sdhb*<sup>-/-</sup>, clone 8) or their wild-type (WT) counterparts (*Sdhb*<sup>lox/lox</sup>) into the flanks of 10-week-old female NMRI-nu mice. Animal experiments were registered by the French Ethical committee under Number 14-041 and followed the ARRIVE guidelines of the National Centre for the Replacement, Refinement, and Reduction of Animals in Research (London, UK).

Tumors were allowed to grow until their size reached  $0.6 \text{ cm}^3$ . They were then resected and  $8 \text{ mm}^3$  fragments were grafted in the dorsal fat pad of naïve nude mice. The tumors grew in 100% of mice and tumors were macroscopically visible after 2 weeks for WT and 1 month for *Sdhb*<sup>-/-</sup> tumors, in line with the reduced growth rate of *Sdhb*<sup>-/-</sup> cells observed *in vitro* (13). Immediately after magnetic resonance spectroscopy,

tumors were retrieved and snap-frozen in liquid nitrogen or fixed in 4% paraformaldehyde.

#### Succinate $^1\text{H}$ -MRS in a 4.7-T animal-dedicated MRI device

Imaging was performed  $37 \pm 11$  days after the graft for the *Sdhb*<sup>-/-</sup> group versus  $22 \pm 7$  days for the WT group. Mice were placed in prone position under isoflurane anesthesia (4% for induction and 1.5% for maintenance in 1 L/min air) with respiration monitoring.

$^1\text{H}$ -MRS was performed in a dedicated small-animal 4.7-T MR system (Biospec 47/40 USR Bruker), using a  $^1\text{H}$  quadrature transmit/receive body coil with a 3.5-cm inner diameter. An anatomical two-dimensional (2D) steady-state free precession sequence (True FISP) was first acquired in two orthogonal planes.  $^1\text{H}$ -MRS was then carried out using an optimized asymmetric Point RESolved Spectroscopy (PRESS) monovoxel acquisition (Supplementary Fig. S1). Echo signals [TR, 3,000 ms; TE, 144 or 272 ms; average, 512, with a VOI size of  $5 \times 5 \times 5 \text{ mm}^3$ ] were acquired during 25 minutes.

The MRS spectrum of succinic acid [ $\text{HOOC}-(\text{CH}_2)_2-\text{COOH}$ ] presents a characteristic peak at 2.44 ppm, corresponding to the precession frequency of the  $\text{CH}_2$  protons. The succinate peak was quantified by measuring the area under the peak using Topspin 2.0 software (Bruker Corporation).

#### Patients

Patients were recruited from the French COMETE ('Cortico et Médullosurrénale: les Tumeurs Endocrines') cohort of the Hypertension unit of the European Georges Pompidou Hospital (HEGP), Paris, France. Ethical approval for the study was obtained from the institutional review board [Comité de Protection des Personnes (CPP) Ile de France II], and written informed consent to participate in the study was obtained from all patients. The procedures used for PPGL diagnosis and genetic testing were in accordance with international clinical practice guidelines (1). Mutation analysis of PPGL susceptibility genes was performed as previously described (28). When patients underwent surgery for paraganglioma, fresh tumor samples were frozen immediately after surgical removal and stored in liquid nitrogen until processing following the COMETE collection procedures. Confirmation of diagnosis was performed by histology on paraffin-embedded, formalin-fixed samples.

#### Succinate detection by $^1\text{H}$ -MRS in patients at 3 T

Combined MR images and MR spectroscopic scans of patients were acquired in a 3 T MRI clinical scanner (Discovery MR750w GEMSOW, GE Medical Systems).  $^1\text{H}$ -MRS spectra were acquired by PRESS on the basis of the PROBE monovoxel sequence (29) and optimized for succinate and lactate detection, with TR, 2,500 ms; TE, 144 ms; Nex: 512 (22-minute acquisition) or 1,024 (44-minute acquisition). The VOI ( $1.3\text{--}19 \text{ cm}^3$ ) was centered on the anatomical image to prevent lipid contamination from the tissue surrounding the tumor as previously described (30).

MR images were acquired using a whole body (GEM Chest/Body/Pelvis; Body 24 AA3) or a head and neck (GEM Head/Neck/Chest; Head 24) phased-array multi-coil.

Detection of tumors and VOI positioning was performed on thin-section high-resolution T2-weighted fast spin-echo imaging in at least two orthogonal planes with the following parameters: TR, 2,500 ms; TE, 85 ms; echo train length, 19; slice thickness,

3 mm; spacing, 0.3; field of view,  $14 \times 14 \text{ cm}^2$  for neck or  $42 \times 42 \text{ cm}^2$  for whole-body coil; matrix,  $320 \times 320$ .

If necessary, an anatomical 2D steady-state free precession sequence (FIESTA CINE) was acquired with TR, 3.7 ms; TE, 1.4 ms; TI, 210 ms; slice thickness, 5 mm; spacing, 1 mm; field of view,  $14 \times 14 \text{ cm}^2$  for neck or  $42 \times 42 \text{ cm}^2$  for whole-body coil and/or a 3D angio-MR at arterial phase, after contrast agent administration of gadoterate meglumine 0.2 mL/kg with TR, 11.4 ms; TE, 2.2 ms; slice thickness, 0.8 mm; spacing, 0.4 mm; field of view,  $30 \times 27 \text{ cm}^2$ .

A prescan algorithm was first acquired to adapt the transmitter and receiver gains and center frequency, the homogeneity of the magnetic field was optimized with the three-plane auto-shim procedure, and water suppression and automatic shimming of the single voxel were performed.

#### Measurement of succinate by gas chromatography/mass spectrometry

Tumor samples from 15 mice (10 samples with *Sdhb* knockout and 5 WT controls) and from paragangliomas of four patients (patients #1, #5, #6, and #9) were processed by organic extraction with ethylacetate, derivatization with *N,O*-bis(trimethylsilyl) trifluoroacetamide with 1% trimethylchlorosilane, and analyzed by gas chromatography/tandem mass spectrometry (GC-MS) on a GC-MS triple quadrupole (Scion TQ, Bruker Daltonics). Analytes were identified according to retention time and mass spectrum in selected reaction monitoring mode on the basis of standard spectral reference libraries.

#### Immunohistochemistry

SDHA, SDHB, and SDHD protein expression were assessed on formalin-fixed, paraffin-embedded (FFPE) tumor samples by immunohistochemistry as previously described (16, 18, 22) using the following antibodies: anti-SDHA (ab14715, Abcam; 1:1,000), anti-SDHB (HPA002868, Sigma-Aldrich Corp; 1:500), and anti-SDHD (HPA045727, Sigma-Aldrich Corp; 1:50).


#### SDH activity

SDH activity was investigated on frozen tumor samples using a spectrophotometrical assay, as previously described (31).

## Results

#### *In vivo* detection of succinate in murine allografted tumors

The  $^1\text{H}$ -MRS sequence was optimized *in vitro* (Supplementary Fig. S1). To investigate whether *in vivo* detection of succinate could be assessed for the noninvasive identification of SDH-related tumors, a proof-of-concept pilot study was performed in a mouse model prior to patients' exploration. No animal model of SDH-related PPGL being available, we generated an allografted mouse model using imCC carrying a homozygous knockout of the *Sdhb* gene or their WT counterparts (13). *Sdhb* knockout in tumors was confirmed by genotyping (Fig. 1A) and measurement of SDH enzymatic activity (Fig. 1B). GC-MS showed a massive accumulation of succinate in SDH-deficient tumors:  $28.3 \pm 9.5 \text{ nmol}$  per mg protein in the *Sdhb*<sup>-/-</sup> group, versus  $0.6 \pm 0.7 \text{ nmol/mg}$  protein in the control groups (Fig. 1C), confirming inhibition of SDH activity in *Sdhb*<sup>-/-</sup> tumors.  $^1\text{H}$ -MRS was first tested in mice using a TE = 272 ms and a fixed VOI size ( $125 \text{ mm}^3$ ) placed over the tumor mass of 13 *Sdhb*<sup>-/-</sup> and 16 WT allografted mice (Fig. 1D). The peak corresponding to lactate, indicative of anaerobic glycolysis, was always present regardless of the tumor type. In

**Figure 1.**

SUCCESS in *Sdhb*<sup>-/-</sup> allografted tumors in mice. A, genotyping of *Sdhb* gene locus in DNA extracted from tumors derived from *Sdhb*<sup>-/-</sup> and WT (*Sdhb*<sup>lox/lox</sup>) cells allografted in mice. The deletion of exon 2 (ex2, 460 bp) is visible in tumors from *Sdhb*<sup>-/-</sup> grafted cells, whereas the floxed allele (900 bp) is shown in the *Sdhb*<sup>lox/lox</sup> grafted mice. In both tumor types, a WT DNA band (845 bp) originating from the supporting cells of the allografted mice (fibroblasts, endothelial cells) is visible. B, *Sdhb*<sup>-/-</sup> derived tumors display an unequivocal decrease in SDH activity measured by spectrophotometry. C, massive accumulation of succinate measured by GC-MS in *Sdhb*<sup>-/-</sup> derived tumors, which is not seen in *Sdhb*<sup>lox/lox</sup>-derived tumors. D, <sup>1</sup>H-MRS spectra of tumor masses in mice allografted with WT (green spectra) or *Sdhb*<sup>-/-</sup> (blue spectra) cells using a TE = 272 ms. The lactate peak was present regardless of the tumor type, whereas the succinate peak was only detected in *Sdhb*<sup>-/-</sup> tumors. E, succinate levels measured *in vitro* by GC-MS correlate with the area under the succinate peaks (AUP) at TE = 272 ms. F, and G, the same data as in A and B, respectively, but at TE = 144 ms.

contrast, the succinate peak was only detected in *Sdhb*<sup>-/-</sup> tumors, with a sensitivity and specificity of 100% ( $n = 13$ ), in agreement with succinate accumulation caused by SDH inhibition (Fig. 1D;

Supplementary Fig. S2A). Measurements of succinate concentrations in *Sdhb*<sup>-/-</sup> tumor samples ( $n = 4$ ) by GC-MS confirmed the MRS results. The succinate levels measured *in vitro* correlated with

**Table 1.** Characteristics of the 9 patients and 10 tumors analyzed by <sup>1</sup>H-MRS at 3 T

Patient	Gender	Age, y	Gene	Mutation type	Multiple locations	Type of tumor analyzed	Largest tumor diameter, mm	VOI size, cm <sup>3</sup>	Succinate level on GC-MS, nmol/mg protein
1	M	33	<i>SDHB</i>	c.740T>Gp.Met247Arg	Yes	VPGL	80	4.6 and 1.5	ND
						APGL	94	19.2	89.3
2	M	70	<i>SDHC</i>	c.397C>Tp.Arg133Ter	No	VPGL	42	3.7	ND
3	F	32	<i>SDHD</i>	c.210G>Tp.Arg70Ser	Yes	CBPGL	24	1.5	ND
4	M	41	<i>SDHD</i>	c.325C>Tp.Gln109Ter	Yes	CBPGL	39	3.6	ND
5	M	25	none	NA	No	PCC	55	6.2	0.84
6	M	60	none	NA	No	APGL	35	4.2	0.54
7	F	74	none	NA	Yes	CBPGL	30	1.3	ND
8	M	47	none	NA	No	PCC	30	5.8	ND
9	M	48	<i>SDHA</i>	c.91C>Tp.Arg31Ter	No	APGL	50	12	72.17

Abbreviations: APGL, abdominal paraganglioma; CBPGL, carotid body paraganglioma; NA, not applicable; ND, not determined; PCC, pheochromocytoma; VPGL, vagal paraganglioma.

the area under the succinate peaks using a TE of 272 ms ( $r^2 = 0.88$ ; Fig. 1E). The results obtained in the 4.7 T magnet with TE = 272 ms were repeated with TE = 144 ms in 5 *Sdhb*<sup>-/-</sup> and 3 WT tumors, (Fig. 1F; Supplementary Fig. S2B). At TE = 144 ms, lactate was hardly detectable, whereas succinate was specifically observed in *Sdhb*<sup>-/-</sup> tumors. Again, GC-MS quantification of succinate performed in *Sdhb*<sup>-/-</sup> resected samples ( $n = 5$ ) correlated with *in vivo* measures ( $r^2 = 0.70$ ; Fig. 1G).

#### *In vivo* detection of succinate in patients

Nine patients presenting with pheochromocytoma, cervical, and/or abdominal paragangliomas were recruited at the Hypertension unit of the European Georges Pompidou Hospital (Table 1). All patients benefited from genetic counseling in accordance with the Endocrine Society Clinical Practice Guidelines (1). Before undergoing SUCCEs with <sup>1</sup>H-MRS, a germline *SDHx* gene mutation was identified in four patients (one *SDHB*, one *SDHC*, and two *SDHD*), whereas no mutation was identified for the other five patients.

Genetic testing identified a variant of unknown significance (VUS) in the *SDHB* gene of Patient #1 (c.740T>G = p.Met247Arg), a 33-year-old male with two paragangliomas and a predominant noradrenergic secretion profile. In the cervical paraganglioma of this patient, the <sup>1</sup>H-MRS signal of succinate was unequivocally discernable at 2.44 ppm using 1,024 averages and a 4.6 cm<sup>3</sup> VOI size (Fig. 2A). Sensitivity and specificity were explored by reducing the scan repeats from 1,024 to 512 averages and the VOI size from 4.6 to 1.5 cm<sup>3</sup>: the succinate peak was still clearly detected in low sensitivity conditions in the cervical paraganglioma (Fig. 2A), as well as in the abdominal tumor mass (Fig. 2B), but not in the liver, showing the persistence of SDH activity in this healthy organ, expected to be heterozygous for the mutation (Fig. 2C). The pathogenicity of this newly described variant suggested by <sup>1</sup>H-MRS was supported by the LOH at the *SDHB* locus in DNA extracted from the resected abdominal paraganglioma (Fig. 2D) and confirmed by three functional tests: *SDHB*-negative (unspecific weak diffuse signal) and *SDHD*-positive immunohistochemistries (Fig. 2E), loss of SDH enzymatic activity (Fig. 2F), and succinate accumulation measured by GC-MS (Fig. 2G).

The succinate peak was observed in the tumors of the three other *SDHx* patients using scan repeats of 1,024 and 512 averages (Supplementary Fig. S3). Interestingly, a choline peak at 3.2 ppm was associated with the succinate peak in each of the *SDHx*-mutated tumors. In contrast, neither succinate nor choline peaks

were observed in tumors from patients without *SDHx* mutations (Fig. 3; Supplementary Fig. S4). In Patient #5, immunohistochemistry of tumor samples showed *SDHB*- and *SDHA*-positive and *SDHD*-negative staining, whereas GC-MS analysis confirmed the absence of succinate accumulation (Fig. 3B and C).


#### Unexpected *SDHA* mutation identified by SUCCEs

Surprisingly, a small but significant peak above baseline was detected in an abdominal paraganglioma from a patient with an apparently sporadic form of the disease (Fig. 4A.) This patient was a 48-year-old man suffering from a single abdominal paraganglioma with no family history of PPGL. Following comprehensive genetic counseling according to the international guidelines, the search for mutations of *SDHB*, *SDHC*, and *SDHD* genes returned negative. Nevertheless, the presence of a succinate peak in the tumor of this patient prompted us to sequence the *SDHA* gene of this patient, which identified a c.91C>T = p.Arg31Ter mutation (Fig. 4B), previously reported in Dutch patients with PPGL (16) or GIST (32). After the patient had undergone surgery, additional analyses of his tumor showed negative *SDHA* and *SDHB* and positive *SDHD* immunohistochemistry (Fig. 4C). GC-MS confirmed the accumulation of succinate (Table 1) and validated the rare and unexpected *SDHA*-mutated status of this patient that had been initially stratified as a sporadic case.

## Discussion

Here, we report the noninvasive detection of succinate by *in vivo* MRS in tumors of patients with PPGL carrying *SDHx* genes mutations but not in those of patients without *SDHx* mutations. Interestingly, in an *Sdhb*<sup>-/-</sup> mouse tumor model, this succinate peak is correlated with the concentrations of succinate measured in the resected tumors by GC-MS.


Demonstration of SDH inactivation is currently based on *in vitro* analyses of tissue samples: immunohistochemical analyses of *SDHB*, *SDHA*, and *SDHD* expression in FFPE tissues (16, 18, 22), direct succinate measurements on frozen tumor samples by nuclear magnetic resonance (NMR) spectroscopy (15, 19, 20, 23), GC-MS, or liquid chromatography mass spectroscopy (LC-MS; refs. 13, 17, 21). Recently, Varoquaux and colleagues reported *in vivo* detection of succinate using <sup>1</sup>H-MRS in 6 patients with head and neck paraganglioma (3 *SDHD*, 1 *SDHB*, and 2 sporadic cases). Although the spectra quality was considered as low in the 2 sporadic cases and uninterpretable in one *SDHD*-mutated tumor, a succinate peak was also only

**Figure 2.**

SUCCESS in a patient with an *SDHB* gene mutation. A, <sup>1</sup>H-MRS spectra of the right cervical paraganglioma (PGL) of Patient #1. A succinate peak was detected in the cervical PGL with two different averages (1,024 and 512) and two different VOI sizes (4.6 and 1.5 cm<sup>3</sup>). B, applying the PRESS sequence to the abdominal tumor mass of the same patient permits to detect a succinate peak. C, in the healthy liver, the absence of a peak demonstrates the specificity of the method. D, genetic testing identified a variant of unknown significance in the *SDHB* gene with an LOH in tumor DNA extracted from the resected abdominal PGL. E, SDHB immunohistochemistry (IHC) leads to an unspecific weak diffuse signal in tumor cells, whereas endothelial cells (arrows) are strongly labeled (top part). A positive staining is shown after SDHD IHC (bottom part). Scale bar, 50 μm. F, significant reduction of SDH activity in Patient #1 (blue line) as compared with Patient #6, a case without *SDHx* mutation (green line). G, High level of succinate in the abdominal PGL of Patient #1 measured by GC-MS.

detected in three *SDHx*-mutated tumors (33). In the present study, we show that <sup>1</sup>H-MRS also detects succinate in abdominal paraganglioma and in genes encoding all four SDH subunits. Moreover, we performed longer acquisition time (512 and 1,024 averages, vs. 120 in the Varoquaux and colleagues study), which allowed an immediate interpretation of spectra, without the need of postprocessing the data.

The benefits of assessing this tumor hallmark in patients with *SDHx*-related tumors are important in several aspects. SUCCESS would allow stratifying these patients or classifying VUS as deleterious mutations with no need of tissue sampling. Patient #9 carried a single abdominal paraganglioma diagnosed at age 48, without a family history for this disease. According to international guidelines, *SDHB*, *SDHC*, and *SDHD* genetic testing were




**Figure 3.** SUCCES in a patient without *SDHx* gene mutation. A, absence of a succinate peak in the <sup>1</sup>H-MRS spectrum of Patient #5's pheochromocytoma (PCC) with 1,024 averages. B, unequivocal positive granular staining after SDHB and SDHA IHC (left) and negativity of SDHD IHC (right). Scale bar, 50 μm. C, low level of succinate in the tumor measured by GC-MS.

performed in this patient, but not *SDHA*, which would have been prescribed only after surgery, in case of *SDHA* negative immunohistochemistry (1). In such a case, exploring the patient with <sup>1</sup>H-MRS and detecting the succinate peak orientated us without hesitation toward *SDHA* sequencing, leading to early identification of the mutation. *SDHA* immunohistochemistry is not included in international guidelines and is not a standard procedure, thus it is likely that this mutation would have been missed in most instances. In Patient #1, an *SDHB* gene VUS was identified, whereas *SDHB* immunohistochemistry showed a potentially

misleading, weak diffuse signal, previously reported in some PPGL with *SDHx* genes mutations (18). Hence, in this other case, the <sup>1</sup>H-MRS succinate peak was particularly informative to validate the functionality of the *SDHB* mutation.

*SDHx* mutation carriers are at risk of developing multiple paragangliomas, and *SDHB*-mutated carriers are predisposed to metastatic forms of the disease. Knowledge of the *SDHx*-mutated status is critical for the follow-up and clinical management of patients and of their relatives. On the basis of an early knowledge of the *SDHx* mutational status, surgeons may decide to



**Figure 4.** SUCCES in a patient with an *SDHA* gene mutation. A, <sup>1</sup>H-MRS spectra in Patient #9's abdominal paraganglioma (PGL). A small succinate peak was detected with 512 averages and a 12 cm<sup>3</sup> VOI size. B, results of genetic testing that identified a c. 91C>T variant in the *SDHA* gene. C, *SDHA* and *SDHB* immunohistochemistry (IHC) lead to unspecific weak diffuse signals in tumor cells whereas endothelial cells are strongly labeled. In contrast, *SDHD* IHC shows a positive staining. Scale bars, 50 μm.

adapt their procedures, especially for *SDHB* cases. For nonoperable tumors, therapeutic choices may also take advantage from this information. For example, studies have suggested that *SDHB* mutation carriers may be better responders to high doses of  $^{131}\text{I}$ -MIBG (34), sunitinib (35), or temozolomide treatments (36). Although these results will need to be evaluated in larger, prospective, and comparative studies, they nevertheless pave the way toward personalized medicine for inherited PPGL.

Overall, the clinical value of SUCCES lies in its capacity to assess for the presence of succinate repeatedly over the time course of the disease, for clinical surveillance, postoperative follow-up, and evaluation of treatment efficacy (17). *In vivo* estimation of succinate could help classifying a dubious lesion detected during surveillance and to demonstrate the causality of SDH deficiency in tumors identified in *SDHx*-mutated patients. This would be particularly helpful in cases for which surgery is not necessary, such as prolactin-secreting pituitary adenomas recently described in *SDHx* mutation carriers (37). Because of the small size of these tumors, the feasibility of SUCCESS may however be more difficult in these cases.

Animal experiments demonstrated that the area under the succinate peak of the  $^1\text{H}$ -MRS spectra is correlated with the concentrations of succinate measured in the resected tumors by GC-MS. Future studies in larger groups will be needed to show whether this correlation holds also in patients. If this turned out to be the case and given that succinate concentrations in tumors reflect the metabolic activity of SDH-deficient tumor cells, then SUCCES would produce a quantifiable surrogate marker of radiation and/or chemotherapy efficacy for the patients.

Interestingly, other metabolites have been shown *in vitro* to discriminate between different types of inherited PPGL (20). In future studies, it may also be addressed whether these metabolites can also be observed by  $^1\text{H}$ -MRS and used as supplemental tools. For example, Imperiale and colleagues recently reported in a case of sporadic pheochromocytoma that catecholamines are indeed detectable by  $^1\text{H}$ -MRS (38).

The present proof-of-concept study has shown that SUCCES is highly sensitive, reliable, and specific for the detection of the *SDHx* mutations that lead to inhibition of SDH activity. The next step to fully define the place of this new method in the clinical management of PPGL is to test the method in larger series of patients and define the best conditions for routine clinical applications. In that respect, we occasionally observed, in both groups of patients, a blunt signal centered at 1.2 ppm. This signal corresponds to adipose tissue surrounding the tumor that is not always straightforward to avoid even with strict intratumor positioning of the VOI in which  $^1\text{H}$ -MRS is performed. Because MRS data are usually displayed with a y scale normalized on the highest peak of the spectrum, the presence of a significant lipid signal may modify the threshold for succinate detection in small lesions. Averaging more spectra increases the signal-to-noise ratio but also increases scan duration, which may not be applicable to all patients. For abdominal tumors, respiratory gating should be considered to reduce the lipid peak and improve the quality of spectra, as previously reported for *in vivo* catecholamine detection (38). Using 512 scan averages appears to be sufficient for reliable succinate detection in tumors with *SDHx* genes mutation. However, this may limit the quality of spectra for small or highly necrotic tumors, as shown in the case of patient #3 (Supplementary Fig. S3B), for whom successful interpretation could only be achieved after 1,024 scan averages. Therefore, the minimal tumor

size for reliable measurements of succinate needs to be addressed in future prospective studies. Fortunately, this  $^1\text{H}$ -MRS sequence is easy to implement in any clinical MRI scanner using standard hardware and software already in place in many imaging departments.

Finally, it is noteworthy that the succinate peak was always associated in human PPGL with a peak resonating at 3.2 ppm on the  $^1\text{H}$ -MRS spectra, most probably corresponding to choline. Such a peak was only seen in tumors from the patients carrying *SDHx* mutations. Previous *in vitro* NMR studies never reported such a choline increase in SDH-related tumors. However, a similar peak is also observed in the spectra of both *SDHx*-mutated paraganglioma evaluated by *in vivo*  $^1\text{H}$ -MRS in the Varoquaux and colleagues study (33). The accuracy of this observation will need to be further validated both *in vivo* and *in vitro*, in SDH as well as in other oncogenic mutations of metabolic pathways. It is worth noting that choline is a methyl donor in the S-adenosylmethionine pathway involved in DNA and histone methylation. Hence, if confirmed, the choline peak that we observed here may be related to the disrupted methylation phenotype recently identified in SDH-deficient tumors (13).

In conclusion, we present here a robust and simple method that can be used routinely to demonstrate the presence of succinate in the tumors of patients with PPGL. Considering its excellent sensitivity, specificity, and innocuousness, SUCCES deserves to be tested in large multicentric series to define its place in the clinical guidelines of PPGL management as well as in other SDH-related tumors such as GIST and renal clear cell carcinomas.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Authors' Contributions

**Conception and design:** C. Lussey-Lepoutre, A. Morin, L. Amar, F. Zinzindohoué, A.-P. Gimenez-Roqueplo, J. Favier, B. Tavitian

**Development of methodology:** C. Lussey-Lepoutre, A. Bellucci, A. Morin, L. Amar, M. Janin, G. Autret, C.-A. Cuenod, J. Favier, B. Tavitian

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** C. Lussey-Lepoutre, A. Bellucci, A. Morin, A. Buffet, L. Amar, M. Janin, C. Ottolenghi, F. Zinzindohoué, G. Autret, N. Burnichon, E. Robidel, B. Banting, S. Fontaine, C.-A. Cuenod, P. Benit, P. Rustin, P. Halimi, J. Favier

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** C. Lussey-Lepoutre, A. Bellucci, N. Burnichon, P. Halimi, B. Tavitian, J. Favier

**Writing, review, and/or revision of the manuscript:** C. Lussey-Lepoutre, L. Amar, M. Janin, C. Ottolenghi, F. Zinzindohoué, G. Autret, N. Burnichon, C.-A. Cuenod, P. Halimi, L. Fournier, A.-P. Gimenez-Roqueplo, J. Favier, B. Tavitian

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** C. Lussey-Lepoutre, A. Morin, F. Zinzindohoué, E. Robidel, B. Banting, S. Fontaine, L. Fournier, A.-P. Gimenez-Roqueplo, J. Favier

**Study supervision:** C. Lussey-Lepoutre, A.-P. Gimenez-Roqueplo, J. Favier, B. Tavitian

## Acknowledgments

The authors thank Prof. Pierre-François Plouin and Dr. Guillaume Bobrie for their clinical contribution to the study and Prof. Catherine Oppenheim and Stephanie Lion for sharing their expertise. They also thank Daniel Balvay for helpful discussions, Brigitte Lambert (Radiology, HEGP) and Marion Uettwiller (General Electrics Healthcare) for technical assistance, and Catherine Tritscher for administrative assistance. They thank the technical staff of the Genetic department of HEGP (especially Françoise Le Quellec, Caroline Travers, Nirubiah Thurairajasingam) led by Prof. Xavier Jeunemaitre, Jean-Michaël

Mazzella, and Samir Jocelyn Do Rego for their contribution to the study. They thank Daniel Tennant for helpful discussion.

## Grant Support

This work received funding from the Cancer Research for Personalized Medicine—CARPEM project (Site de Recherche Intégré sur le Cancer- SIRIC), the Agence Nationale de la Recherche (ANR-2011-JCJC-00701 MODEOMAPP), the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 259735, and the Institut National du Cancer et la Direction Générale de l'Offre de Soins (INCa-DGOS\_8663) for the COMETE network.

C. Lepoutre-Lussey is funded by the CARPEM project. A. Bellucci received a fellowship from Fondation pour la Recherche Médicale. A. Buffet received a fellowship from the ITMO Cancer - Plan Cancer 2014-2019.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 2, 2015; revised September 16, 2015; accepted October 6, 2015; published OnlineFirst October 21, 2015.

## References

- Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2014;99:1915-42.
- Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and pheochromocytoma: from genetics to personalized medicine. *Nat Rev Endocrinol* 2015;11:101-11.
- Janeway KA, Kim SY, Lodish M, Nose V, Rustin P, Gaal J, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. *Proc Natl Acad Sci U S A* 2011;108:314-8.
- Vanharanta S, Buchta M, McWhinney SR, Virta SK, Peczkowska M, Morrison CD, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. *Am J Hum Genet* 2004;74:153-9.
- Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. *Science* 2000;287:848-51.
- Warburg O. Ueber den stoffwechsel der tumoren. Constable, London. 1930.
- Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat Genet* 2002;30:406-10.
- Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 2009;360:765-73.
- Morin A, Letouze E, Gimenez-Roqueplo AP, Favier J. Oncometabolite-driven tumorigenesis: From genetics to targeted therapy. *Int J Cancer* 2014;135:2237-48.
- Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL-EVA Investigators. *J Clin Endocrinol Metab* 2013;98:E162-73.
- Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. *J Clin Endocrinol Metab* 2007;92:3822-8.
- Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespín M, Nau V, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant pheochromocytomas. *Cancer Res* 2003;63:5615-21.
- Letouze E, Martinelli C, Lorient C, Burnichon N, Abernethy N, Ottolenghi C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. *Cancer Cell* 2013;23:739-52.
- Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-1 $\alpha$  prolyl hydroxylase. *Cancer Cell* 2005;7:77-85.
- Imperiale A, Moussallieh FM, Roche P, Battini S, Cicek AE, Sebarg F, et al. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. *Neoplasia* 2015;17:55-65.
- Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. *J Clin Endocrinol Metab* 2011;96:E1472-6.
- Lendvai N, Pawlosky R, Bullova P, Eisenhofer G, Patocs A, Veech RL, et al. Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings. *Endocrinology* 2014;155:27-32.
- Menara M, Oudijk L, Badoual C, Bertherat J, Lepoutre-Lussey C, Amar L, et al. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma. *J Clin Endocrinol Metab* 2015;100:E287-91.
- Rao JU, Engelke UF, Rodenburg RJ, Wevers RA, Pacak K, Eisenhofer G, et al. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma. *Clin Cancer Res* 2013;19:3787-95.
- Rao JU, Engelke UF, Sweep FC, Pacak K, Kusters B, Goudswaard AG, et al. Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics. *J Clin Endocrinol Metab* 2015;100:E214-22.
- Richter S, Peitzsch M, Rapizzi E, Lenders JW, Qin N, de Cubas AA, et al. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. *J Clin Endocrinol Metab* 2014;99:3903-11.
- van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, et al. An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. *Lancet Oncol* 2009;10:764-71.
- Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1 $\alpha$  in tumours which result from germline FH and SDH mutations. *Hum Mol Genet* 2005;14:2231-9.
- Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by *in vivo* spectral-editing and 2D correlation magnetic resonance spectroscopy. *Sci Transl Med* 2012;4:116ra4.
- Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. *Nat Med* 2012;18:624-9.
- Elkhalel A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. *Sci Transl Med* 2012;4:116ra5.
- Harada K, Honmou O, Liu H, Bando M, Houkin K, Kocsis JD. Magnetic resonance lactate and lipid signals in rat brain after middle cerebral artery occlusion model. *Brain Res* 2007;1134:206-13.
- Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. *Hum Mol Genet* 2011;20:3974-85.
- Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. *Magn Reson Med* 1994;31:365-73.
- Agarwal M, Chawla S, Husain N, Jaggi RS, Husain M, Gupta RK. Higher succinate than acetate levels differentiate cerebral degenerating cysticerci from anaerobic abscesses on in-vivo proton MR spectroscopy. *Neuroradiology* 2004;46:211-5.
- Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, Saudubray JM, et al. Biochemical and molecular investigations in respiratory chain deficiencies. *Clin Chim Acta* 1994;228:35-51.
- Oudijk L, Gaal J, Korpershoek E, van Nederveen FH, Kelly L, Schiavon G, et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. *Mod Pathol* 2013;26:456-63.

33. Varoquaux A, le Fur Y, Imperiale A, Reyre A, Montava M, Fakhry N, et al. Magnetic resonance spectroscopy of paragangliomas: new insights into *in vivo* metabolomics. *Endocr Relat Cancer* 2015;22: M1–8.
34. Gonias S, Goldsby R, Matthey KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. *J Clin Oncol* 2009;27:4162–8.
35. Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. *Curr Oncol Rep* 2013;15: 356–71.
36. Hadoux J, Favier J, Scoazec JY, Leboulleux S, AlGhuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. *Int J Cancer* 2014;135:2711–20.
37. Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA, et al. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in human and mice. *J Clin Endocrinol Metab* 2015;jc20144297.
38. Imperiale A, Battini S, Averous G, Mutter D, Goichot B, Bachellier P, et al. *In vivo* detection of catecholamines by magnetic resonance spectroscopy: a potential specific biomarker for the diagnosis of pheochromocytoma. *Surgery*. 2015 May 1. [Epub ahead of print].